Search Our Site

News filed in:

"article"

 How Manufacturers, Middlemen, Providers, PBMs, and the Government Are Keeping Us in the Dark • The healthcare industry is rife with secrets                     • Drugs and device efficacies are elusive • Prices are kept opaque                                                         • Payers/patients lack clarity Someone got screwed. I mean that literally, though not in that way. I have a patient’s… Read More »

[...]

Read More

AbbVie is accused of paying kickbacks, using a stealthy network of nurses to promote Humira

Column Title In a wide-ranging scheme, AbbVie (ABBV) used a combination of old-fashioned kickbacks to doctors and a stealthy network of nurses to illegally boost prescriptions of its best-selling Humira treatment, according to a lawsuit filed on Tuesday by the California insurance commissioner. Over a five-year period, the drug maker offered physicians a familiar menu of... Read More »

Read More →

Column Title In a wide-ranging scheme, AbbVie (ABBV) used a combination of old-fashioned kickbacks to doctors and a stealthy network of nurses to illegally boost prescriptions of its best-selling Humira treatment, according to a lawsuit filed on Tuesday by the California insurance commissioner. Over a five-year period, the drug maker offered physicians a familiar menu of… Read More »

[...]

Read More

Google DeepMind’s AI can detect over 50 sight-threatening eye conditions

Chris Jackson/Getty Images A focus on artificial intelligence could lead to fewer people losing their sight. Tech industry insiders regularly herald AI as the solution to all of our problems, included those posed by health care. London-based DeepMind, owned by Google’s parent company, Alphabet, focuses heavily on the specifics of using artificial intelligence in health... Read More »

Read More →

Chris Jackson/Getty Images A focus on artificial intelligence could lead to fewer people losing their sight. Tech industry insiders regularly herald AI as the solution to all of our problems, included those posed by health care. London-based DeepMind, owned by Google’s parent company, Alphabet, focuses heavily on the specifics of using artificial intelligence in health… Read More »

[...]

Read More

$173,000,000 Reason Why You Should Rethink Your Auto-Adjudication Strategy

A few years ago Advanced Medical Strategies (AMS) published an article covering how current auto-adjudication systems left much to be desired. Does auto-adjudication save money? Sure. It easily sorts through the low-hanging fruit, processing a large number of claims both cheaply and swiftly. However, it generally fails when it comes to these three booming components:... Read More »

Read More →

A few years ago Advanced Medical Strategies (AMS) published an article covering how current auto-adjudication systems left much to be desired. Does auto-adjudication save money? Sure. It easily sorts through the low-hanging fruit, processing a large number of claims both cheaply and swiftly. However, it generally fails when it comes to these three booming components:… Read More »

[...]

Read More

Oncimmune Holdings plc Launches EarlyCDT®-Liver Test in the US

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announced that it has completed development of its EarlyCDT®-Liver test for hepatocellular carcinoma (HCC), and that it will be commercially available from today in the US. The test has high specificity at 97% and... Read More »

Read More →

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announced that it has completed development of its EarlyCDT®-Liver test for hepatocellular carcinoma (HCC), and that it will be commercially available from today in the US. The test has high specificity at 97% and… Read More »

[...]

Read More

AHA, AARP blast big pharma for not doing enough to curb drug price increases

American Hospital Association President and CEO Rick Pollack, along with the CEO of the American Association of Retired Persons Jo Ann Jenkins, called out the pharmaceutical industry for not doing its part to cut healthcare costs. Pollack and Jenkins cited recent research showing that drug prices have continued to spike in recent years at alarming... Read More »

Read More →

American Hospital Association President and CEO Rick Pollack, along with the CEO of the American Association of Retired Persons Jo Ann Jenkins, called out the pharmaceutical industry for not doing its part to cut healthcare costs. Pollack and Jenkins cited recent research showing that drug prices have continued to spike in recent years at alarming… Read More »

[...]

Read More

Science hinted that cancer patients could take less of a $148,000-a-year drug. Its maker tripled the price of a pill

A group of cancer doctors focused on bringing down the cost of treatments by testing whether lower — and cheaper — doses are effective thought they had found a prime candidate in a blood cancer drug called Imbruvica that typically costs $148,000 a year. The science behind Imbruvica suggested that it could work at lower... Read More »

Read More →

A group of cancer doctors focused on bringing down the cost of treatments by testing whether lower — and cheaper — doses are effective thought they had found a prime candidate in a blood cancer drug called Imbruvica that typically costs $148,000 a year. The science behind Imbruvica suggested that it could work at lower… Read More »

[...]

Read More

Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative

An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide. The treatment is expected to cost $300 for 12 weeks, or $3.50 per day,... Read More »

Read More →

An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide. The treatment is expected to cost $300 for 12 weeks, or $3.50 per day,… Read More »

[...]

Read More

Experts Tell Congress How To Cut Drug Prices

The nation’s most influential science advisory group will tell Congress today that the U.S. pharmaceutical market is not sustainable and needs to change. “Drugs that are not affordable are of little value and drugs that do not exist are of no value,” said Norman Augustine, chair of the National Academies of Sciences, Engineering and Medicine’s... Read More »

Read More →

The nation’s most influential science advisory group will tell Congress today that the U.S. pharmaceutical market is not sustainable and needs to change. “Drugs that are not affordable are of little value and drugs that do not exist are of no value,” said Norman Augustine, chair of the National Academies of Sciences, Engineering and Medicine’s… Read More »

[...]

Read More

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or... Read More »

Read More →

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or… Read More »

[...]

Read More

Page 1 of 3

Categories
Archives